RET and non-small cell lung carcinoma: In a recent Chinese retrospective study of 232 patients with RET fusion + NSCLC, they confirmed that most of them (>80%) were PD-L1 negative or intermediate, and, among the 35 evaluable patients, 86% had low m-TMB (<10 mutations per Mb).